Speaker
Description
Preclinical studies tend to suffer from an unacceptably low rate of replicability, which is highly problematic since unreliable results from animal trials cannot provide a sound foundation for subsequent clinical research. Numerous factors contribute to this issue, including the misapplication of statistical methods, poor study design, and inadequate reporting of results. Although specific guidelines for conducting and reporting animal studies exist, entrenched practices within the preclinical research community have proven difficult to change. To our knowledge, this is the first systematic study to assess the quality of research proposals for preclinical studies. We analyzed more than 300 applications for animal trials submitted to the Medical University of Vienna between 2014 and 2019, systematically extracting key indicators based on the ARRIVE guidelines into a database. In addition, we identified over 100 publications resulting from these proposals and again extracted corresponding indicators. Based on these data, we developed quality scores for both proposals and publications and will report results separately for each. Furthermore, we will discuss strategies to improve the current situation. In future work, we will also conduct a joint analysis to compare the quality of proposals with that of the resulting publications.
85717600604